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Protein homeostasis, proteostasis, is essential to understand cell function. Protein degradation is a crucial component of the proteo-
static mechanisms of the cell. Experiments on protein degradation are nowadays present in many investigations in the field of
molecular and cell biology. In the present paper, we focus on the diﬀerent experimental approaches to study protein degradation
and present a critical appraisal of the results derived from steady-state and kinetic experiments using detection of unlabelled and
labelled proteinmethodologies with a proteostatic perspective. This perspective allows pinpointing the limitations in interpretation
of results and the need of further experiments and/or controls to establish “definitive evidence” for the role of protein degradation
in the proteostasis of a given protein or the entire proteome. We also provide a spreadsheet for simple calculations of mRNA and
protein decays for mimicking diﬀerent experimental conditions and a checklist for the analysis of experiments dealing with protein
degradation studies that may be useful for researchers interested in the area of protein turnover.
1. Introduction: Cellular Proteostasis
The living cell requires a homeostatic control of energy, use,
and production to accomplish the diﬀerent cell functions.
Proteins are the main producers, users and transformers of
energy. The set of proteins that are present in a cell at a given
time is what we call the cell proteome. The cellular proteome
has to take care of itself and its behaviour determines cell
function. Accordingly, the proteome has its own homeostasis
that is necessarily coupled, at least, to energy homeostasis.
Protein homeostasis, proteostasis, is critical for the adapta-
tion of cell function to a fluctuating internal and external
milieu. Those adaptative responses, like regular exercise for
us, keep the proteome in good “shape.” The proteostatic
mechanisms of a cell involve a complex network of pathways
that includes protein synthesis, folding, posttranslational
modifications (PTMs), protein-protein interactions (PPIs),
subcellular localization, and degradation. Protein expression
levels in eukaryotes are determined by several processes,
beginning with nuclear gene expression. Nuclear gene tran-
scription, pre-mRNA processing, mRNA nuclear transport,
and degradation (Figure 1, BOX 1) are the initial steps
determining the available pool of cell mRNAs that can be
translated, the translatome, the total mRNAs that are in
ribosome complexes undergoing translation (Figure 1, BOX
2). The life of a protein begins as a nascent polypeptide by
translation of its mRNA (Figure 1, BOX 2). The “survival” or
“demise” of the nascent polypeptides and the newly synthe-
sized proteins is under control. Many cellular proteins can be
degraded at this early stage of its biogenesis, including those
that are defective that constitutes the so-called defective
ribosomal products (DRiPs) and that could potentially
account for up to 30% of the polypeptides synthesized by a
mammalian cell [1]. In this early stage, correct folding of the
newly synthesized proteins to its functional tertiary and qua-
ternary structures (Figure 1 BOX 3) is assisted by dedicated
chaperones that also play an important role in reverting
misfolding [2]. Specific PTMs and PPIs of the nascent, newly
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Figure 1: Schematic diagram of cell proteostasis. The boxes illustrate the diﬀerent cellular process involved in protein homeostasis. BOX 1,
nucleus, where gene transcription and pre-mRNA processing produce the mature mRNA that will be transported to the cytoplasm where
it could be degraded (mRNA decay can also take place in the nucleus). The mRNA is engaged, mainly in the cytoplasm, to translation by
the ribosomal machinery producing a nascent polypeptide that grows to a newly synthesized protein (BOX 2). The folding of the newly
synthesized proteins, helped by chaperones, results in the “so-called” native protein structure either monomeric or oligomeric (BOX 3, only
a dimer is shown for simplicity). Both the newly synthesized proteins and the mature mono or oligomeric forms of proteins are subjected
to post-translational modification (PTM) and specific and unspecific protein-protein interactions (PPIs) that are illustrated in BOX 4.
Proteins due to changes in its native conformation produced by diﬀerent physical and/or chemical perturbations of the cell, or by mutations,
could get misfolded or misprocessed and misfolded. The misfolded proteins, perhaps under the influence of PPIs and PTMs, will produce
protein aggregates or soluble oligomeric protofibrils that eventually may form amyloid fibers (BOX 5). The degradation of proteins (BOX
6) is mainly due to the ubiquitin-proteasome System (UPS, nucleus and cytoplasm, 20S, and 26S proteasome) and the autophagic pathways
(cytoplasmic): mainly chaperone-mediated authopagy (CMA) andmacroautophagy (autophagy). Other proteases also participate in protein
degradation (calpains, caspases, etc.), not shown. Blue lines connect all the boxes to the central circular box of protein degradation (BOX 6)
indicating that proteolysis can regulate any of the process and vice versa. Black arrows connecting boxes indicate the “flow” of the products
depicted in each BOX.
synthesized or the mature native proteins are due to their
living circumstances in a general crowded environment con-
trolled by thermal motion and diﬀusion rates (Figure 1, BOX
4) with an estimated protein concentration close to 30mM
[3]. Due to physical and/or chemical modification, native
proteins may get misfolded given rise to the formation of
aggregates or protofibrils which eventually organized into
amyloid fibers (BOX 5). The ubiquitin proteasome and
autophagic pathways (Figure 1, BOX 6) are the main path-
ways of general protein degradation. PTMs and PPIs together
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with subcellular localization determine protein degradation
by those pathways. The subcellular localization of proteins
certainly contributes to their proteostasis: protein traﬃcking,
folding, and regulation of degradation of the specific trans-
latome for mitochondria (chloroplasts), the endoplasmic
reticulum, and the secretary pathway; the peroxisomes and
the cell nucleus have mechanistic diﬀerences from the cyto-
plasmic protein proteostasis [4–8]. In addition, the localiza-
tion ofmRNAs and the translational machinery in the cell are
also highly relevant to proteostasis. A special case is neurons
that have specialized compartmentalization, dendrites, and
axons. Transport of some mRNAs and the translational
machinery to those distant places from the neuronal cell
soma and the retrograde transport to the soma are crucial
step to maintain proteostasis at dendrite and axons, but they
may also exist proteostatic mechanisms at those locations
likely to be both quantitatively and qualitatively diﬀerent
from soma proteostasis [9, 10]. Finally, cellular proteostasis
may be controlled by signalling pathways in a cell-nonauto-
nomous manner that remain to be identified [11].
The energetic cost of the production and maintenance of
a healthy proteome is critical to determine life sustainability
and is probably one of the reasons why protein and energy
homeostasis have coevolved to allow the appearance of com-
plexity. Accordingly, their regulatory mechanisms have
important crosstalks and are well conserved during evolution
[12]. Energy and/or protein homeostasis failure leads to cell
dysfunction and eventually to cell death, as may occur
during aging, neurodegenerative diseases [13], and possibly
in other chronic human diseases; diabetes, cancer, renal and
pulmonary fibrosis, and so forth. Certain proteins, like toxic
metabolites, can become proteotoxic and the cell has also
mechanisms to cope with those toxic proteins (Figure 1,
BOX 5), in particular for misfolded or aggregated proteins
[14]. The global connection of energy and protein home-
ostasis is also supported by recent experiments showing that
significant increase of life span results from reduction of
insulin/IGF signaling or by loss of VHL/HIF1, that also
improves function of transgenic models of proteotoxic
diseases as reported for C. elegans [15, 16] and mice [17].
Studies on protein turn-over are used by many
researchers in many diﬀerent areas of cellular and molecular
biology, but sometimes the interpretations of the results are
leading to incorrect conclusions. This paper deals with the
experimental approaches used to study protein degradation
in a quantitative basis and how a critical appraisal of the
interpretations of the results in the framework of proteostasis
would certainly help to arrive to appropriate conclusions,
knowing what we can reasonably conclude from each
experimental setup.
2. Steady-State versus Kinetic Studies
By definition, the steady-state level of each protein of a cell
proteome is attained when its rate of synthesis and its rate
of degradation are equal, invariant respect to time. Also by
definition, except in the quiescent state, cells will grow and
divide generating two daughter cells; as a consequence, the
entire proteome is diluted by the increase in cell volume
due to cell division cycle. Each protein of the proteome will
have its own steady-state levels, and changes in the steady-
levels are the result of changes in the rate of protein synthesis
and/or the rate of protein degradation.
The rate of synthesis of the entire proteome of a cell is
controlled by the relative abundance of the diﬀerent mRNAs
of the transcriptome, whose diﬀerent steady-state levels are
also the result of mRNA synthesis and degradation, and by
their translational rate. The actual amount of a protein being
synthesized is the product of the copy number of mRNA
molecules and the number of protein molecules synthesized
by unit time per mRNA molecule. The rate of degradation
of mRNAs or proteins is generally assumed to follow an
exponential decay, similar to the familiar radioactive decay
of an isotope. Accordingly, the changes over time of the
amount of a cell protein can be expressed with the following
diﬀerential equation, taken from Belle et al. [18],
P(t) = dP
dt
=M(t)∗ R− P(t)∗ (D +V), (1)
where P is the protein concentration, M is the copy number
of the mRNA, R is the rate of translation per mRNA mole-
cule, D is the protein degradation rate constant, and V is the
growth rate (volume increase factor per unit time). At steady
state, the rate of protein synthesis and degradation are equal,
and as a consequence, dP/dt = 0, no change in the amount of
protein over time. The steady-state levels of a protein can be
defined by the following equation, also taken from Belle et al.
[18],
(P0) = M(0)∗ R
D +V
. (2)
We provide an on-line spreadsheet that allows for easy graph-
ical visualization of the rate of protein degradation after the
introduction of diﬀerent values for the terms of the diﬀeren-
tial equation: number of RNA molecules, rate of mRNA
translation, mRNA half-life, protein half-life, and cell dou-
bling times.
Nowadays, the heavy/light isotope pulse-labelling
approach, stable isotope labeling by amino acids in cell
culture (SILAC), followed by mass spectrometry- (MS-)
based quantitative proteomics, is the method of choice to
measure protein turn-over rates under steady-state condi-
tions [19, 20] and in a proteomic scale. The SILAC/MS
methodologies when possible, and others like the isobaric
tag for relative and absolute quantification (iTRAQ), are
presently used to measure degradation rates (half-lives) of
proteins. These methodologies can also be used to compare
relative protein abundance in cells that have been subjected
to a stimulus, moving from one to another steady state and
even for single cell analysis [21]. New technical developments
are being designed that may allow the inclusion of the study
of PTMs eﬀects on protein turn-over changes in response to a
cell stimulus or stress [22]. Nevertheless, more “traditional”
methods to measure protein turn-over are still widely used.
There are two basic experimental designs: measuring the
amount of a certain protein before and very long after a cell
4 Biochemistry Research International
perturbation and measuring the changes in protein concen-
trations by kinetic, time-course experiments. In the first
approach, enough time is provided after cell perturbation to
ensure that the cell moves from the initial to a new steady
state. In this steady-state situation, the observed changes in
protein levels can be attributed to either changes in protein
synthesis or degradation, or to both, changes in synthesis and
degradation. In the kinetic approach, time-course experi-
ments, the contribution of each of the branches (synthesis
and degradation) to the new steady state after cell perturba-
tion is studied. The analysis of these approaches will be the
focus of the following sections of this paper.
3. Pharmacological and Genetic Interference
Studies of Protein Degradation
The most common experimental setup to study protein
degradation is to measure changes in protein levels mainly by
protein immunoblot of total cell extracts. The pharmacolog-
ical interference to study protein degradation is performed
by treatment of cells with protein synthesis and/or degrada-
tion inhibitors. Genetic interference to study protein degra-
dation targets either transcription or mRNA function. Tran-
scriptional downregulation of mRNA expression is achieved
by the use of Tet-on or Tet-oﬀ transcriptional control of the
corresponding gene. The function of mRNA is targeted by
specific siRNA or shRNA that results in RNA decay and/or
inhibition of protein synthesis of the targeted mRNA.
3.1. Pharmacological Interference Studies of Protein Degrada-
tion. One of the simplest experiments is to add an inhibitor
of protein degradation to the cells, wait overnight or 24 h,
and then compare the levels of the protein of interest between
the untreated and the treated cells by simple immunoblot
of total cell extracts. When the results obtained show an
increase in the protein levels, the usual conclusion is that the
protein is being degraded by the degradation pathway that is
“specifically” blocked by the inhibitor. When there is no
change or a decrease in the protein levels, the particular
pathway of degradation blocked by the specific inhibitor does
not participate in the degradation of the protein. Those con-
clusions seem appropriate, but can be incorrect. Most of
those experiments are performed after prolonged incubation
times (as mentioned above), and as a consequence, they are
measuring changes in the “steady-state” levels of a protein.
The new steady-state level of a protein after treatment with
an inhibitor of protein degradation can be reached kinetically
by changes in its degradation rate with a constant rate of syn-
thesis, by changes in its rate of synthesis, or by both changes
in synthesis and degradation. As a consequence, in those
experiments further experiments are needed, before reaching
a conclusion. Those controls should include the study of the
possible eﬀects of inhibitors of protein degradation on the
rate of synthesis of the protein under study. Specifically to
measure changes in the transcription (or decay) of the cor-
responding mRNA that may result in an increase (decrease
or no change) in the number of RNA molecules being
translated or even the actual rate of mRNA translation in the
presence and in the absence of the protein degradation
inhibitor.
The aforementioned situation is very clearly exemplified
by the broadly used proteasome inhibitors. Those inhibitors
are “very specific,” but the ubiquitin-proteasome degrada-
tion pathway is also implicated in transcriptional control.
The ubiquitin-proteasome pathway participates in the degra-
dation of transcription factors limiting the transcriptional
output, and also in recycling of transcriptional complexes on
chromatin to facilitate multiple rounds of transcription [23–
25] aﬀecting the amounts of mRNA available for trans-
lation. As a consequence, if the gene encoding the protein
whose degradation is being studied is controlled at the trans-
criptional or posttranscriptional levels (mRNA processing,
nuclear export, mRNA decay, or translation) by the ubi-
quitin-proteasome pathway, part of the change in steady-
state protein levels could be explained by modulation of
those upstream mechanisms (Figure 1, aﬀected processes
depicted in BOXES 1 and 2). Those upstream processes
become especially relevant for proteins with a short half-life
(minutes to a few hours).We have shown that transcriptional
upregulation of the CMV promoter is the major cause of
the increased protein levels of unstable fluorescent reporter
proteins after treatment of cells with proteasome inhibitors,
and not as much to its decreased rate of degradation by inhi-
bition of the proteasome [26]. The steady-state levels of the
unstable fluorescent proteins under basal conditions are very
low for a given rate of synthesis and degradation (steady
state), the increase in the amounts of the unstable protein by
treatment with proteasome inhibitors cannot be accounted
by the same rate of protein synthesis as in the basal condi-
tions and simple inhibition of the degradation of the unstable
protein. In fact, the increase in protein levels of unstable
fluorescent proteins in the presence of proteasome inhibitors
can be prevented by cotreatment of the cells with transcrip-
tional inhibitors [26]. The same caveat also applies for pro-
teins with longer half-lives, but in this case the eﬀect observed
may be masked due to the higher abundance of those
proteins under steady-state conditions that makes more diﬃ-
cult to observe significant changes by immunoblotting.
A similar situation applies to the interpretation of the
eﬀect of proteasome inhibitors in time-course experiments.
As an example from published results, let us analyze recent
papers on the eﬀect of proteasome inhibitors on the ubiqui-
tinome (total ubiquitylated proteins of a cell) protein land-
scape. Two recent studies [27, 28] state that changes in the
abundance of the ubiquitinome are not reflective of overt
protein accumulation in response to addition of proteasome
inhibitors to the cells. This statement does not mean that
there are no clear changes in the abundance of diﬀerent pro-
teins. In the time-course study of HCT116 cells treated with
1 μM bortezomib reported by Kim et al. [27], the average
change in protein accumulation is 1.5-fold after 8 h of treat-
ment (for more than 4500 and less than 5744 protein being
analyzed). The corresponding average increase for ubiquity-
lated modified peptides is 2.8-fold. As the authors already
point out that they could not analyze many known low-
abundance canonical ubiquitin-proteasome targets, their
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conclusion should be taken with caution. Further cautions
apply to those studies; do not get blinded by high numbers
and the use of log2 scales for expressing the results. An aver-
age increase of 1.5-fold in the total abundance of the “pro-
teome” after treatment of cells with proteasome inhibitors for
8 h is a tremendous energetic burden for the cell proteostasis,
mainly energy expenditure for protein synthesis and folding,
and a small fraction of this accumulation could be explained
by inhibition of protein degradation (see below). These
results clearly show the potent eﬀect of proteasome inhibitors
on global regulation of gene expression, but the details are
also interesting. For example, the key enzyme controlling
glycolysis, phosphofructokinase (PFK), has a half-life of 40–
70 h (depending on the isozyme) as recently determined by
a SILAC-MS proteomic studies in HeLa and C2C12 cells
[29], and is not expected to be very diﬀerent in HCT116.
Accordingly, treatment of cells with 1 μM bortezomib for up
to 8 h should not change significantly the total amount of
PFK in the cell by inhibition of its degradation. In contrast,
Kim et al. [27] report that the abundance of PFK isozymes
increase threefold (1.5 on log2 scale used by the authors) after
8 h of incubation of the cells with the proteasome inhibitor.
These changes have obvious consequences from the point of
view of the regulation of glycolysis and can only be explained
by increased protein synthesis, likely due to increased gene
transcription, pre-mRNA processing or translation of the
corresponding PFKmRNAs. Kim et al. [27] show an increase
in HIF1α levels by immunoblot analysis, not observed by
the SILAC-MS experiments because HIF1α is a low abun-
dance protein not detected with the proteomic technologies.
Accordingly, the changes in PFK protein levels could be
attributed, at least in part, to an increase in gene tran-
scription due to the stabilization of HIF1α by proteasome
inhibitors, as HIF1α is a well-known activator of PFK gene
transcription during hypoxia [30]. The eﬀects reported by
Udeshi et al. [28] after treatment of the cells for 4 h with
5 μM of a less specific proteasome inhibitor, MG132, are not
as extensive in the whole proteome but still are highly sig-
nificant. The expected eﬀects on protein levels by treatment
of cells with proteasome inhibitors are time-dependent as
transcription, processing, and translation are needed before
a change in protein levels can be observed, and 4 h is enough
time to observe those eﬀects translated into protein levels.
The above analysis further strength our conclusion,
always consider possible eﬀects on transcription and transla-
tion in the interpretation of the results obtained when using
inhibitors of protein degradation, as exemplified with pro-
teasome inhibitors. The rational of this consideration seems
obvious for experiments with a prolonged time of incuba-
tions (steady state) but also applies for time-course experi-
ments that require >2–4 h of treatment of the cells with those
inhibitors to observe a significant eﬀect in protein levels. A
similar scenario is encountered in experiments where the
eﬀects of so-called “toxic” proteins accumulated in neurode-
generative diseases are studied. Those “toxic” proteins have
clear eﬀects on gene transcription and posttranscriptional
regulation of mRNA, independent of their possible eﬀects on
protein degradation [31–33]. In summary, the contribution
of changes in the copy number of mRNA molecules and
translational rate has always to be taken into account for the
correct interpretation of the results of experiments with pro-
tein degradation inhibitors or expression of “toxic” proteins
under steady-state conditions and in time-course experi-
ments.
The most common kinetic experiments are usually per-
formed by treatment of cells with protein synthesis inhibitors
(cycloheximide, emetine, and anisomycin) provided that cell
toxicity is controlled by the analysis of cell viability along
the time course of the experiment. In this experimental
approach, translation is surely inhibited, but also RNA pol
I and RNA pol III transcription are inhibited, without aﬀect-
ing general RNA pol II transcription [34], actually some
pol II genes can even increase its transcriptional rate in the
presence of protein synthesis inhibitors. Besides those eﬀects,
there is also a cell response to translational arrest. Protein
synthesis inhibitors have also a very potent activating eﬀect
on stress kinases, JNK, and SAPK [35] and also ERK1/2 in the
presence of growth factors [36] that leads to the activation
of c-fos, fos B, c-jun, junB, and jun D and transcription of
genes regulated by those transcription factors. Accordingly,
if the protein under study is subjected to PTM by those
stress kinases, both the eﬀect of protein synthesis inhibition
and changes in PTMs of the protein, likely aﬀecting also its
PPIs, could be implicated in the rate of degradation observed
under those conditions. The role of PTM and PPIs in the reg-
ulation of the degradation rate of proteins has many exam-
ples in the literature [37], and their eﬀects on a proteomic
scale are beginning to be studied [22, 29]. The point made
here is that PTMs and PPIs have always to be considered as
a possible mechanism that may modify the interpretation of
the results obtained by the use of protein synthesis inhibitors.
Another possible situation is that the protein under study
is poorly degraded even after prolonged incubation of the
cells with protein synthesis inhibitors. Those results could be
due to the actual fact that the protein under study has a very
long half-life or alternatively that a protein with a shorter
half-life is required to interact with the specific protein under
study in order to be targeted to degradation. It is also note-
worthy to recall that protein synthesis inhibitors also aﬀect
the machinery of degradation, with inhibitory eﬀects on
the multicomponent ubiquitin-proteasome [38–40] and
autophagic pathways [41]. The combined use of protein syn-
thesis and degradation inhibitors in time-course experiments
is the most usual experimental setup to study the role of
diﬀerent proteolytic degradation pathways, and the consid-
erations made above should also be taking into account for
the interpretation of the results of these combined pharma-
cological experiments.
3.2. Genetic Interference Studies of Protein Degradation.
Transcriptional shut-oﬀ (Tet-on, Tet-oﬀ) by tetracycline res-
ponsive promoters of protein expression [42] and mRNA
translational inhibition and/or mRNA degradation using
siRNA or shRNA [43] are the main genetic methods to
knock-down the mRNA levels encoding for the protein
whose degradation is being investigated or for determining
the role of a protein in the degradation of another protein.
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The correct interpretation of the results of these genetic inter-
ference methods requires understanding that mRNA degra-
dation, and/or translation inhibition, is a time-dependent
process. Accordingly, a new steady state of the protein
levels will be attained concomitantly with the decay of the
corresponding mRNA and/or its translational inhibition,
either after transcriptional shutdown of gene expression
(Tet-on/oﬀ systems) or by inhibition of translation and/or
degradation in the case of siRNA and shRNAs. Using the
spreadsheet available on-line, the reader can model diﬀerent
experimental situations to simulate this type of experiments.
If the half-life of the mRNA is much shorter than the actual
half-life of the protein, the experimental results obtained in
a shut-oﬀ transcriptional or RNA interference experiment
will allow the accurate determination of the half-life of the
protein. In any other situation, the mRNA half-life (and/or
the rate of translational inhibition) will determine the rate
of disappearance of the protein measured by immunoblot of
total cell extracts. As a consequence, to correctly interpret the
results obtained in both types of genetic interference setups,
the rate of decay of the mRNA and/or translation inhibition
(easily determined by pulse radioactive experiments and
immunoprecipitation) has to be evaluated. Unfortunately,
those control experiments are frequently not considered
when using those methodologies. As an example, this
criticism applies to the studies of alpha-synuclein half-life in
cells using the Tet-on/oﬀ methodology [44, 45]; those studies
do not take into account that their results on the half-life
of the protein are aﬀected by the rate of decay of the alpha-
synuclein mRNA. As a consequence, their conclusions about
the regulation of the degradation of alpha-synuclein are not
correctly validated.
4. Pulse-Chase Experiments
Pulse-chase experiments are done either with the traditional
radioactive aminoacids (35S-Met, Cys, or 14C aminoacids)
followed by total radioactive count or immunoprecipitation
with specific antibodies to the protein under study or the
heavy/light isotope pulse labelling, SILAC, followed by mass
spectrometry- (MS-) based quantitative proteomics (see
comments above, under steady-state versus kinetic studies).
Traditional pulse-chase experiments measure the rate of
degradation of newly synthesized proteins. The newly syn-
thesized proteins followed a maturation process (folding and
in most cases oligomerization) and may be subjected to
specific PTMs and could present unique PPIs that may diﬀer
considerably from those of the preexisting proteins (already
mature proteins) in the cell. As a consequence, is conceivable
that the rate of degradation of the newly-synthesized
(labelled) proteins may be diﬀerent from the rate of degra-
dation of the proteins pre-existing in the cell as measured,
for example, by treatment of the cells with protein synthesis
inhibitors. There are factors that must be taken into account
in those traditional pulse-chase experiments. Before the
pulse with the radioactive aminoacids, cells are usually
starved for aminoacids during variable time periods to
deplete the endogenous pool of the aminoacid that will be
used for protein labelling. During the starvation period cells,
respond to aminoacid starvation by activating the ubiquitin-
proteasomal pathway earlier than the activation of the
autophagic pathway, producing an increase in protein degra-
dation rates of pre-existing proteins in order to ensure the
continuation of aminoacid supply for de novo protein syn-
thesis [46]. Proteasome inhibitors are usually tested in this
experimental setup to inhibit protein degradation by the
ubiquitin-proteasome pathway, with the eﬀects already
described in the previous section. As a consequence, keeping
to a minimum, the time of aminoacid starvation and pulse-
radioactive labelling (total 30min–2 h) is a good experi-
mental practice. Furthermore, if proteasome inhibitors are
used (as discussed above) it may be required to perform
pulse-chase experiments in the absence and in the presence
of protein synthesis inhibitors during the chase period,
to control for the possible increase in mRNA abundance
due to transcriptional and posttranscriptional eﬀects of
proteasomal inhibitors.
5. Using Tagged Proteins
Inmany occasions when antibodies against the protein under
study are not available, or in order to study the eﬀect of
mutations on protein stability, expression of proteins with
a tag is used to study protein degradation. This technique
allows easy identification of the protein by immunoblot
or by immunoprecipitation with specific antitag antibodies.
Another variant is the use of fusion constructs of the protein
of interest with fluorescent or luminescent proteins. The
general assumption behind those experiments is that the
fusion of the protein of interest with any tag will show the
same behaviour as the untagged protein. Any protein fused to
a “big” tag, like GFP or luciferase or “medium” tags, like TAP
(Tandem Aﬃnity Purification), is “suspect” of misbehaviour
from the point of view of its degradation rates, unless exper-
imental evidence shows the opposite. This situation is espe-
cially critical when the degradation rate of the whole pro-
teome is being evaluated with the “big” and “medium” tag
methodology. The above caveat has already been pointed out
in a recent publication [47], where the authors compare the
estimated half-lives obtained by the ratios of GFP-fused pro-
teins [48] and by SILAC/MS-based quantitative proteomics
[19], showing big discrepancies. Another caveat with the use
of tagged proteins, even if there are “small tags” as Flag,
HA, Myc, V5, and so forth, is the location of the tag within
the protein sequence. Most often the tag is fused either
to the N- or the C-terminus of the protein under study. Very
few studies take into consideration that the tag may aﬀect the
protein structure, its PTMs and PPIs or even its subcellular
localization and rate of degradation. We will illustrate here
the relevance of N- and C-terminal tagging with our own
studies on DJ-1 degradation, a dimeric protein whose muta-
tions are associated with early onset Parkinson’s disease [49].
One of those mutations L166P disrupts dimer formation and
the mutant protein has no significant secondary structure
being a direct substrate for the 20S/26 proteasome [49]. In
the studies of the degradation of the mutant DJ-1 L166P by
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cell transfection, we have compared the degradation of the
untagged DJ-1 L166P with the N-terminal flag tagged and
C-terminal V5-flag tag version in HeLa cells. As shown in
Figure 2, the half-life of the untagged protein is rather short.
Tagging the protein with Flag-tag at the N-terminus greatly
increase the half-life of the protein, while tagging at its
C-terminus with V5 flag produced no significant eﬀect.
Accordingly, the behaviour of N-tagged and untagged DJ-1
L166P proteins cannot be expected to be the same. In sum-
mary, if possible, for protein degradation studies (actually
in any type of studies) is better to use untagged proteins and
express them to levels not very diﬀerent from the endogenous
expression levels. When unavoidable, experiments should be
performed with proteins tagged at the N- and C- terminus to
clarify that the results are independent of the location of the
tag.
6. Subcellular Localization and
Protein Degradation
There are many examples from the literature showing that
the degradation of certain proteins can take place in diﬀerent
cell compartments by diﬀerent mechanisms, and those
proteins change their subcellular localization (determined by
PPIs and PTMs) after a cell stimuli or stress, and a special
case, as mentioned in the introduction, is neurons [9]. The
ideal experimental setup to study protein degradation will
be to quantitate the rate of degradation of a protein directly
within its subcellular compartment (nucleus, cytoplasm,
mitochondria, etc.) by a direct method. The problem is simi-
lar to determine the actual rate of an enzyme in the cell with-
out disrupting the cell for biochemical analysis, only NMR
imaging can do it and still for a few enzymatic reactions.
The use of fluorescent fusion proteins allows direct imaging
and quantitation, but the caveats of this experimental
approach for studying protein degradation has already being
mentioned (see above), both at a proteomic scale and for
studying a single protein. Nevertheless, the use of tagged
proteins seems technically unavoidable at present. New semi-
or noninvasive cell techniques are needed to be able to study
the “in situ” degradation rates of proteins within its subcel-
lular location in intact cells.
7. Checklist for Critical Appraisal of
Protein Degradation Studies
A simple way to evaluate studies on protein degradation is to
have in mind, or at hand, a simple scheme like the one pre-
sented in Figure 1 and to ask the following question. How
many boxes of Figure 1 are not considered (lack of informa-
tion) in the interpretation of the data obtained or presented?
This is followed by the question: any of the processes in those
boxes, black boxes in the study because of lack of informa-
tion, are likely to aﬀect interpretation of the results? The rule
of the thumb is as follows: as many black boxes the study
has, as much uncertainty will have the interpretation of the
results. Nothing spectacular, everybody knows it.
Here we are providing a checklist for a critical appraisal of
the design and interpretation of protein degradation studies.
The main points to consider when analyzing a study of the
role of protein degradation on the changes in protein cellular
levels are as shown in Table 1.
Note that the experimental evidence obtained with the
diﬀerent methodologies, excluded the SILAC/MS steady-
state experiments, is only partial and requires further experi-
mental data and controls. Specific comments of the checking
list for the analysis of an experiment or project on protein
degradation follows.
Tick on 1. Studying the degradation of untagged proteins is the
best approach to begin with the study of the degradation of a
protein. Preferentially the endogenous levels of the protein in
the cell should be studied. Alternatively, DNA constructs of
the protein can be transfected in cells with a gene knock out
for the protein under study. In this latter case, the expression
levels of the transfected protein construct should be similar
to those present in wild-type cells. The latter is also a good
approach to study stability of mutant proteins in the absence
of expression of the wild-type protein. The transfection
experiments in knock-out cells are of little use if the lack of
expression of the protein under study is known, or expected,
to alter significantly the proteome or cell proteostasis by any
mechanism, unless those are the objectives of the research.
Tick on 2. Using tagged proteins is not a very good approach.
If unavoidable, perform controls with tagging at the N- and
C-terminus of the protein and check if the results diﬀer
significantly.
Ticks on 1 or 2, 3 or 4, and 7. Tagged or untagged protein
steady-state or kinetic experiments with inhibitors of protein
degradation. The changes in the protein levels cannot be attri-
buted to changes in protein degradation rate. Compulsory to
do control experiments: to measure the amounts of mRNA,
especially if proteasome inhibitors are used (they aﬀect tran-
scriptional rates), for the protein of interest and even the rate
of translation of its mRNA. Treatment with inhibitors of pro-
tein degradation may also aﬀect PTM of the protein under
study (PPIs and subcellular localizationmay be also aﬀected);
remember protein kinases and phospatases are also subjected
to control by degradation.
Ticks on 1 or 2, 4, and 5. Tagged or untagged protein kinetic
experiment with inhibitors of protein synthesis. The changes
in protein levels may be attributed to protein degradation of
pre-existing protein in the cell. Additional required evidence
should be provided as follows: cell viability during the time-
course experiments and also that there are no changes of
PTMs, PPIs, and subcellular localization of the protein under
study in the presence of protein synthesis inhibitors.
Ticks on 1 or 2, 4, 5, and 7. Tagged or untagged protein kinetic
experiment with inhibitors of protein synthesis and degrada-
tion. The changes in protein levels may be attributed to protein
degradation of pre-existing proteins in the cell. The inhibitors
of protein degradation can be added at the same time as pro-
tein synthesis inhibitors or earlier. Prolonged preincubation
periods of the cells with inhibitors of degradation should be
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Figure 2: Degradation of untagged andN-terminus and C-terminus tagged versions of humanDJ-1 L166P. The untagged humanDJ-1 L166P
(hDJ-1 L166P) construct has been described previously [49]. The C-terminal His-V5 tagged hDJ-1 L166P was obtained by PCR amplification
with the following oligonucleotides (forward BamH1-DJ-1; 5′GGAAGGATCCATGGCTTCCAAAAGAGCTCTGG 3′ and reverse Nonstop-
hDJ-1; 5′GTCTTTAAGAACAAGTGGCGCCTTCACTTGAGC 3′) and cloned into pcDNA 3.1/V5-His Topo vector from Invitrogen The
N-terminal 3xFlag- tagged hDJ-1 L166P was obtained by PCR amplification with the following oligonucleotides (forward BamH1-hDJ-1
and reverse XhoI-hDJ-1 5′GCGCCTCGAGCTAGTCTTTAAGAACAAGTGGAGCC 3′) and cloned into the pCMV-3Tag 1-A vector. N2a cells
were cultured in DMEMmediumwith 10%FBS and transiently transfected with the diﬀerent hDJ-1 L166P constructs. Transfected cells were
treated with cycloheximide (20 μg/mL) for the times indicated and analyzed byWestern immunoblotting with anti-hDJ-1specific antibodies,
as described in [49]. Results presented are expressed as mean ± s.e.m for at least three independent experiments.
Table 1
Type of study Conclusion
1  Untagged protein Good approach
2  Tagged protein Not a good approach
3  Usual steady state Partial evidence
4  Kinetic (time-course) Partial evidence
5  Protein synthesis inhibitor Partial evidence for pre-existing proteins in the cell
6  Radioactive pulse-chase experiment Partial evidence for newly synthesized proteins
7  Inhibitors of protein degradation Partial evidence
8  Tet-on Tet-oﬀ, RNA interference Partial evidence
9  SILAC-MS steady-state experiments under basal conditions (turn-over) Good evidence
10  SILAC-MS upon cell stimulus or stress Partial evidence
avoided, as it may change the levels of the protein due to
changes in transcription, mRNA stability, translation, and
so forth. Furthermore, long preincubation may also alter
the expression levels of many proteins, possibly resulting in
a modification of PTMs or PPIs of the protein under study,
obviously aﬀecting its rate of degradation. Always consider
that PTMs, PPIs, and subcellular localization can be aﬀected
by the use of protein synthesis and degradation inhibitors.
Ticks on 1 or 2, 4, and 8. Tagged or untagged protein kinetic
experiment with genetic interference. The decrease in protein
levels cannot be attributed exclusively to protein degradation.
Compulsory to measure the decay (time-course) of the
mRNA (Tet-on/Tet-oﬀ experiments), and decay of mRNA
and/or translational inhibition (RNA interference experi-
ments), in order to be able to interpret the results. Perform
other kinetic experiments to validate the data obtained. The
on-line spreadsheet can be used as a help to interpret the
results.
Ticks 1 or 2, 4, 7, and 8. Tagged or untagged protein
kinetic experiment with genetic interference and inhibitors
of protein degradation. The changes in protein levels cannot be
attributed exclusively to protein degradation. Compulsory to
measure rate (time-course) decay of the mRNA (Tet-on/Tet-
oﬀ experiments) and decay of mRNA and/or translational
rate (RNA interference experiments) in the absence and in
the presence of protein degradation inhibitors. The on-line
spreadsheet can be used as a help to interpret the results.
Ticks on 1 or 2 and 6. Tagged or untagged protein using pulse-
chase radioactive experiments. The decrease in the levels of
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the labelled protein can be attributed to degradation of the
newly synthesised protein. The rate of degradation of the
newly synthesized protein may not be identical to the
rate of the degradation of the pre-existing protein in the
cell. The rates will be similar (or identical) when protein
folding, PTMs, PPIs, and subcellular localization of the newly
synthesized protein are much faster processes than the rate of
degradation of the protein.
Ticks on 1 or 2, 6, and 7. Tagged or untagged protein using
pulse-chase radioactive experiments with inhibitors of pro-
tein degradation. The changes in the levels of the labelled pro-
tein can be attributed to degradation of the newly synthesised
protein.The rate of degradation of the newly synthesized pro-
tein may not be identical to the rate of the degradation of the
pre-existing protein. The inhibitors of protein degradation
are routinely added at the beginning of the chase period, and
they can produce a change in the amount of mRNAs or
mRNA translational rate (see above) producing a faster chase
and decreasing the estimated value of the half-life of the
protein. Addition of protein degradation inhibitors during
the aminoacid starvation before the pulse or along with the
pulse may be needed for proteins with short half-life (<2 h).
In those cases, again, the presence of protein degradation
inhibitors could aﬀect the rate of protein synthesis and as a
consequence, the initial amounts of the radioactive protein
under study could be diﬀerent respect to the controls. Under
these experimental conditions is generally assumed that
inhibitors of protein degradation do not aﬀect protein fold-
ing, PPIs, PTM, and subcellular localization of the newly syn-
thesized protein, but it could not be the case.
Ticks on 1 or 2, 5, 6, and 7. Tagged or untagged protein using
pulse-chase radioactive experiments with inhibitors of pro-
tein synthesis and degradation. The changes in the levels of the
labelled protein can be attributed to degradation of the newly
synthesised protein and can be compared with the degradation
rate of pre-existing protein in the cell. This experimental setup
allows the comparison of the rate of degradation of the newly
synthesized protein (pulse-chase) and that of the pre-existing
protein by addition of the protein synthesis inhibitors during
the chase period. In essence, performing immunoprecipita-
tion experiments of radioactive total cell extracts together
with determination of total protein levels by immunoblot
analysis. If the degradation of the newly synthesized protein
is inhibited by the presence of protein synthesis inhibitors,
it could indicate that another protein(s) with a shorter half-
life than the protein under study is required for targeting the
protein under study to degradation. Alternatively, it could
indicate that PTMs or PPIs changes in response to protein
synthesis inhibitors aﬀect the degradation of the newly syn-
thesized protein. Apply also the same cautions respect to the
use of inhibitors of protein degradation as in previous
entries.
Ticks on 1 or 2 and 9. Tagged or untagged protein using
steady-state SILAC/MS experiments. The calculated changes
in the levels of the labelled protein can be attributed to protein
degradation under steady-state conditions. By comparison of
the rates of disappearance of the heavy/light and appearance
of the light/heavy peptides after the shift in the SILAC exper-
iments, the degradation rate of a protein under steady-state
conditions can be estimated. This methodology seems the
best suited to estimate protein turnover under unperturbed
cell conditions. The half-life values obtained are average
values resulting from the interplay of the rates of the diﬀerent
processes involved in protein homeostasis (Figure 1). At
present, the results reported by diﬀerent groups have strong
variability that can be due to the use of diﬀerent cell lines, but
it might also reflect technical problems related to handling,
processing of the samples, MS sequence coverage of the
proteins, and also to calculations.
Ticks on 1 or 2 and 10. Tagged or untagged protein using
kinetic SILAC/MS after cell stimulus or stress. The calculated
changes in the levels of the labelled protein cannot be attributed
to protein degradation exclusively. Any perturbation of the
steady state of a cell by a stimulus or stress, like treatment
of cells with inhibitors of protein synthesis or degradation,
needs to show that the changes in degradation rates cannot
be explained by changes in other proteostatic processes
(Figure 1), changes in the protein abundance due to tran-
scriptional, posttranscriptional processing of RNA (includ-
ing mRNA transport and decay), or changes in protein
synthesis, folding, oligomerization, PTMs, and PPIs as a con-
sequence of the stimuli or stresses applied to the cells.
8. Conclusion
Interpretation of studies of protein degradation requires, as
with other biological experiments, a critical assessment of
the methodology and the data obtained. A rigorous analysis
will prevent misleading conclusions. Examining the data
obtained by asking a series of simple proteostatic questions
can uncover serious deficiencies. Sometimes it could be
diﬃcult to interpret the data, and to present a balanced and
impartial summary may be not an easy task. However, failing
to do a critical analysis is damaging for science. This situation
is especially relevant in a time of massive “omic” data
availability. The incorrect interpretation of the enormous
amounts of data obtained, together with the postdata com-
putational analysis by merging of actual data on protein
degradation with human classifications of the properties of
proteins (GO terms, pI, unstructured elements, molecular
weight, etc.), may produce many papers and holistic con-
clusions that in a few years could generate a completely new
whole field of science “mislead omics.”
Note 1. Since this review was submitted, a report has appear-
ed [50] describing that DJ-1 L166P promotes cell death by
dissociating Bax from Bcl-XL. Unfortunately the authors
used N-Terminal Flag DJ1 L166P for their experiments, and
as shown here Flag-DJ-1 L166P (Figure 2) has a reduced rate
of degradation compared to the untagged version, and as a
consequence has higher cellular steady-state protein levels
than the untagged DJ-1 L166P. As PPIs are governed by
Law of Mass Action (equilibrium constant), the interactions
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reported for the N- Flag-DJ-1 L166P may not be quan-
titatively relevant for the natural (untagged) DJ-1 L166P.
Accordingly, the eﬀect of DJ-1L166P on apoptosis would be
minimal or even not existent.
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